Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function
Corresponding Author
Michael Wilschanski
Pediatric Gastroenterology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Address correspondence and reprint requests to Prof Michael Wilschanski, Pediatric Gastroenterology Unit, Hadassah Hebrew University Medical Center, POB 24035, Jerusalem, Israel (e-mail: [email protected]).Search for more papers by this authorYasmin Yaakov
Pediatric Gastroenterology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorIbrahim Omari
Pediatric Gastroenterology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorMunir Zaman
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth, Israel
Search for more papers by this authorCamilia R. Martin
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth, Israel
Search for more papers by this authorMalena Cohen-Cymberknoh
CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorDavid Shoseyov
CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorEitan Kerem
CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorDeborah Dasilva
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth, Israel
Search for more papers by this authorSunil Sheth
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth, Israel
Search for more papers by this authorAhmet Uluer
Boston Children's Hospital, Harvard Medical School, Boston
Search for more papers by this authorBrian P. O'Sullivan
University of Massachusetts Medical School, Worcester, MA
Search for more papers by this authorSteven Freedman
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth, Israel
Search for more papers by this authorCorresponding Author
Michael Wilschanski
Pediatric Gastroenterology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Address correspondence and reprint requests to Prof Michael Wilschanski, Pediatric Gastroenterology Unit, Hadassah Hebrew University Medical Center, POB 24035, Jerusalem, Israel (e-mail: [email protected]).Search for more papers by this authorYasmin Yaakov
Pediatric Gastroenterology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorIbrahim Omari
Pediatric Gastroenterology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorMunir Zaman
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth, Israel
Search for more papers by this authorCamilia R. Martin
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth, Israel
Search for more papers by this authorMalena Cohen-Cymberknoh
CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorDavid Shoseyov
CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorEitan Kerem
CF Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorDeborah Dasilva
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth, Israel
Search for more papers by this authorSunil Sheth
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth, Israel
Search for more papers by this authorAhmet Uluer
Boston Children's Hospital, Harvard Medical School, Boston
Search for more papers by this authorBrian P. O'Sullivan
University of Massachusetts Medical School, Worcester, MA
Search for more papers by this authorSteven Freedman
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth, Israel
Search for more papers by this authorThis study was partly supported by a grant from the North American CF Foundation.
The authors have no conflicts of interest.
ABSTRACT
Objectives:
Nasal potential difference (NPD) measurement is part of the diagnostic criteria for cystic fibrosis (CF) and now used routinely as an endpoint in clinical trials of correcting the basic defect in CF. Intestinal current measurement (ICM), measured ex vivo on a rectal biopsy, has been used to study cystic fibrosis transmembrane conductance regulator (CFTR) function but has not been compared to NPD in the same subject in adults and children. The aim of the study is to evaluate the potential usefulness of ICM as a marker of CFTR function for treatment studies compared NPD in patients with CF and in healthy control subjects.
Methods:
ICM and NPD were performed on healthy controls and patients with CF. The healthy adults were individuals undergoing routine screening colonoscopy at the Beth Israel Deaconess Medical Center. The healthy children were undergoing colonoscopy for suspicion of inflammation in Hadassah Hebrew University Medical Center. The CF adults were recruited from Boston Children's Hospital CF Center and CF Center Worcester Mass, the children with CF from Hadassah CF Center.
Results:
ICM measurements in healthy control subjects (n = 16) demonstrated a mean (±SE) carbachol response of 16.0 (2.2) μA/cm2, histamine response of 13.2 (2.1) μA/cm2 and a forskolin response of 6.3 (2.0) μA/cm2. Basal NPD of −15.9 (1.9) and response to Cl− free + isoproterenol of −13.8 (2.0). These responses were inverted in CF subjects (n = 12) for ICM parameters with carbachol response of −3.0 (0.5) μA/cm2, histamine −1.0 (0.8) μA/cm2 and a forskolin response of 0.5 (0.3) and also for NPD parameters; basal NPD of −42.2 (4.3) and response to Cl− free + isoproterenol of 4.3 (0.7). Pearson correlation test showed the comparability of ICM and NPD in assessing CFTR function.
Conclusions:
ICM is equivalent to NPD in the ability to distinguish patients with CF from controls and could be used as surrogate markers of CFTR activity in treatment protocols.
REFERENCES
- 1.Scriver CR, Beaudet AL, Sly WS, et al. The metabolic and molecular bases of inherited disease. Biochemistry (Moscow) 2002; 67:5: 611–12.
10.1023/A:1017418800320 Google Scholar
- 2.Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008; 153: S4–S14.
- 3.Durie PR. Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut 2007; 56: 1153–1163.
- 4.Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science (New York, NY) 1989; 245: 1073–1080.
- 5.Castellani C, Cuppens H, Macek M Jr, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cystic Fibros 2008; 7: 179–196.
- 6. Clinical and Functional Translation of CFTR (CFTR2). http://www.cftr2.org/. Accessed August 15, 2016.
- 7.Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. The J Pediatr 1998; 132: 589–595.
- 8.Desmarquest P, Feldmann D, Tamalat A, et al. Genotype analysis and phenotypic manifestations of children with intermediate sweat chloride test results. Chest 2000; 118: 1591–1597.
- 9.Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994; 331: 974–980.
- 10.Stewart B, Zabner J, Shuber AP, et al. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 899–903.
- 11.Ooi CY, Dupuis A, Ellis L, et al. Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis? Thorax 2014; 69: 254–260.
- 12.De Boeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61: 627–635.
- 13.Mall M, Bleich M, Kuehr J, et al. CFTR-mediated inhibition of epithelial Na+ conductance in human colon is defective in cystic fibrosis. Am J Physiol 1999; 277: G709–G716.
- 14.Mall M, Bleich M, Schurlein M, et al. Cholinergic ion secretion in human colon requires coactivation by cAMP. Am J Physiol 1998; 275: G1274–G1281.
- 15.Hug MJ, Tummler B. Intestinal current measurements to diagnose cystic fibrosis. J Cyst Fibros 2004; 3 (suppl 2): 157–158.
- 16.Mall M, Hirtz S, Gonska T, et al. Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. J Cyst Fibrosi 2004; 3 (suppl 2): 165–169.
- 17.Knowles MR, Carson JL, Collier AM, et al. Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am Rev Respir Dis 1981; 124: 484–490.
- 18.Veeze HJ, Sinaasappel M, Bijman J, et al. Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. Gastroenterology 1991; 101: 398–403.
- 19.Sinaasappel M, Veeze HJ, De Jonge HR. New insights into the pathogenesis of cystic fibrosis. Scand J Gastroenterol Suppl 1990; 178: 17–25.
- 20.Cohen-Cymberknoh M, Yaakov Y, Shoseyov D, et al. Evaluation of the intestinal current measurement method as a diagnostic test for cystic fibrosis. Pediatr Pulmonol 2013; 48: 229–235.
- 21.Wilschanski M, Famini H, Strauss-Liviatan N, et al. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J 2001; 17: 1208–1215.
- 22.Bronsveld I, Mekus F, Bijman J, et al. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest 2001; 108: 1705–1715.
- 23.Bagheri-Hanson A, Nedwed S, Rueckes-Nilges C, et al. Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study. BMC Pulm Med 2014; 14: 156.
- 24.De Boeck K, Derichs N, Fajac I, et al. Diagnostic Network Working Group; EuroCareCF WP3 Group on CF diagnosisNew clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fibros 2011; 10 (suppl 2): S53–S66.
- 25.Sousa M, Servidoni MF, Vinagre AM, et al. Measurements of CFTR-mediated Cl- secretion in human rectal biopsies constitute a robust biomarker for cystic fibrosis diagnosis and prognosis. PLoS One 2012; 7: e47708.
- 26.Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011; 183: 1463–1471.
- 27.Sermet-Gaudelus I, Girodon E, Huet F, et al. Nasal potential difference in cystic fibrosis diagnosis of very young children. J Pediatr 2007; 150: e34–e35.
- 28.De Boeck K, Kent L, Davies J, et al. on behalf of the European Cystic Fibrosis Society Clinical Trial Network Standardisation CommitteeCFTR biomarkers: time for promotion to surrogate endpoint? Eur Respir J 2013; 41: 203–216.
- 29.Ooi CY, Dupuis A, Gonska T, et al. Does integration of various ion channel measurements improve diagnostic performance in cystic fibrosis? Ann Am Thorac Soc 2014; 11: 562–570.
- 30.Mall M, Bleich M, Kuehr J, et al. CFTR-mediated inhibition of epithelial Na+ conductance in human colon is defective in cystic fibrosis. Am J Physiol 1999; 277: G709–G716.
- 31.Mall M, Wissner A, Seydewitz HH, et al. Defective cholinergic (Cl-) secretion and detection of K+ secretion in rectal biopsies from cystic fibrosis patients. Am J Physiol Gastrointest Liver Physiol 2000; 278: G6170–G6224.
- 32.Farrell PM. The meaning of “early" diagnosis in a new era of cystic fibrosis care. Pediatrics 2007; 119: 156–157.
- 33.Farrell PM, Lai HJ, Li Z, et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough!. J Pediatr 2005; 147: S30–S36.
- 34.Narzi L, Ferraguti G, Stamato A, et al. Does cystic fibrosis neonatal screening detect atypical CF forms? Extended genetic characterization and 4-year clinical follow-up. Clin Genet 2007; 72: 39–46.
- 35.Boyle MP. Nonclassic cystic fibrosis and CFTR-related diseases. Curr Opin Pulm Med 2003; 9: 498–503.
- 36.Wallis C. Atypical cystic fibrosis-diagnostic and management dilemmas. J R Soc Med 2003; 96 (suppl 43): 2–10.
- 37.Derichs N, Sanz J, Von Kanel T, et al. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax 2010; 65: 594–599.
- 38.Sheth S, Shea JC, Bishop MD, et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Human genetics 2003; 113: 286–292.
- 39.Gelrud A, Sheth S, Banerjee S, et al. Analysis of cystic fibrosis gener product (CFTR) function in patients with pancreas divisum and recurrent acute pancreatitis. The American journal of gastroenterology 2004; 99: 1557–1562.
- 40.Bishop MD, Freedman SD, Zielenski J, et al. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Human genetics 2005; 118: 372–381.
- 41.Jaron R, Yaakov Y, Rivlin J, et al. Nasal potential difference in non-classic cystic fibrosis-long term follow up. Pediatric pulmonology 2008; 43: 545–549.
- 42.Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372: 719–727.
- 43.Southern KW, Noone PG, Bosworth DG, et al. A modified technique for measurement of nasal transepithelial potential difference in infants. The Journal of pediatrics 2001; 139: 353–358.
- 44.Mall M, Kreda SM, Mengos A, et al. The DeltaF508 mutation results in loss of CFTR function and mature protein in native human colon. Gastroenterology 2004; 126: 32–41.
- 45.Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004; 350: 560–569.
- 46.Clancy JP, Szczesniak RD, Ashlock MA, et al. Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function. PLoS One 2013; 8: e73905.
- 47.Graeber SY, Hug MJ, Sommerberg O, et al. Intestinal current measurements detect activation of murant CFTR in patients with cystic fibrosis with the G551D mutation treated by Ivacaftor. Am J Crit Care Med 2015; 192: 1252–1255.
Citing Literature
